📊 BDSX Key Takeaways
Investment Thesis
Biodesix exhibits severe financial distress with negative stockholders' equity of -2.5M, persistent operating losses, and significant cash burn despite 24% revenue growth. The company is consuming cash at an unsustainable rate (-23.5M FCF annually) while carrying 50M in long-term debt, creating an acute solvency risk in the near term.
BDSX Strengths
- Revenue growth of 24.1% YoY demonstrates market demand for diagnostic services
- Current ratio of 1.86x provides near-term liquidity cushion with 19.0M in cash
- Active insider participation (28 Form 4 filings in 90 days) suggests management confidence
BDSX Risks
- Negative stockholders' equity (-2.5M) indicates technical insolvency and heightened bankruptcy risk
- Operating losses of -27.9M on 88.5M revenue with -39.8% net margin shows business model is fundamentally unprofitable at scale
- Negative free cash flow of -23.5M annually with only 19.0M cash on hand implies liquidity crisis within 12 months without capital raise or operational turnaround
- 50M long-term debt burden is unsustainable given negative cash generation and equity cushion
Key Metrics to Watch
- Quarterly cash burn rate and months of cash runway remaining
- Path to operating profitability and gross margin expansion
- Debt refinancing activities and covenant compliance status
BDSX Financial Metrics
💡 AI Analyst Insight
BIODESIX INC presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BDSX Profitability Ratios
BDSX vs Healthcare Sector
How BIODESIX INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BDSX Balance Sheet & Liquidity
BDSX 5-Year Financial Trend
5-Year Trend Summary: BIODESIX INC's revenue has grown significantly by 62% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.64 indicates the company is currently unprofitable.
BDSX Growth Metrics (YoY)
BDSX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $18.2M | -$8.7M | $-1.16 |
| Q2 2025 | $17.9M | -$10.8M | $-0.08 |
| Q1 2025 | $14.8M | -$11.1M | $-0.08 |
| Q3 2024 | $13.5M | -$10.3M | $-0.07 |
| Q2 2024 | $11.9M | -$10.8M | $-0.08 |
| Q1 2024 | $9.1M | -$13.6M | $-0.14 |
| Q3 2023 | $11.1M | -$10.9M | $-0.14 |
| Q2 2023 | $11.0M | -$13.4M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BDSX Capital Allocation
BDSX SEC Filings
Access official SEC EDGAR filings for BIODESIX INC (CIK: 0001439725)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BDSX
What is the AI rating for BDSX?
BIODESIX INC (BDSX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BDSX's key strengths?
Revenue growth of 24.1% YoY demonstrates market demand for diagnostic services. Current ratio of 1.86x provides near-term liquidity cushion with 19.0M in cash.
What are the risks of investing in BDSX?
Negative stockholders' equity (-2.5M) indicates technical insolvency and heightened bankruptcy risk. Operating losses of -27.9M on 88.5M revenue with -39.8% net margin shows business model is fundamentally unprofitable at scale.
What is BDSX's revenue and growth?
BIODESIX INC reported revenue of $88.5M.
Does BDSX pay dividends?
BIODESIX INC does not currently pay dividends.
Where can I find BDSX SEC filings?
Official SEC filings for BIODESIX INC (CIK: 0001439725) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BDSX's EPS?
BIODESIX INC has a diluted EPS of $-4.67.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.